Download PDF
Semin Respir Crit Care Med 2018; 39(02): 213-218
DOI: 10.1055/s-0037-1615799
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Community-Acquired Respiratory Viruses

Jens Gottlieb
1   Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
26 March 2018 (online)

    Permissions and Reprints

Abstract

The incidence of community-acquired respiratory viruses (CARVs) is ∼15 cases per 100 patient-years after lung transplantation (LTx). Paramyxoviruses account for almost 50% of the cases of CARV infection in LTx. Most patients will be symptomatic with a mean decline of 15 to 20% in forced expiratory volume in 1 second. The attributable death rate is low in recent years 15 to 25% CARV infected LTx patients will develop chronic lung allograft dysfunction within a year after CARV infection. This risk seems to be increased in comparison to the noninfected LTx recipient.

Detection rate of CARV dependent on clinical awareness, sampling, and diagnostic method with nucleic acid testing by polymerase chain reaction in bronchoalveolar lavage is the gold standard after LTx.

There is no approved treatment for paramyxoviruses, most centers use ribavirin by various routes. Toxicity of systemic ribavirin is of concern and some patients will have contraindication to this treatment modality. Treatment may reduce the risk to develop chronic lung allograft dysfunction and respiratory failure. Agents under development are inhibiting viral attachment and use silencing mechanisms of viral replication.

Keywords

lung transplantation - community-acquired respiratory viruses - ribavirin - bronchiolitis obliterns syndrome
 

  • References

  • 1 Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet 2011; 377 (9773): 1264-1275
    CrossrefPubMedGoogle Scholar
  • 2 Shalhoub S, Husain S. Community-acquired respiratory viral infections in lung transplant recipients. Curr Opin Infect Dis 2013; 26 (04) 302-308
    PubMedGoogle Scholar
  • 3 Braciale TJ, Sun J, Kim TS. Regulating the adaptive immune response to respiratory virus infection. Nat Rev Immunol 2012; 12 (04) 295-305
    CrossrefPubMedGoogle Scholar
  • 4 Meyer KC, Raghu G, Verleden GM. , et al; ISHLT/ATS/ERS BOS Task Force Committee; ISHLT/ATS/ERS BOS Task Force Committee. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J 2014; 44 (06) 1479-1503
    CrossrefPubMedGoogle Scholar
  • 5 Boehler A, Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J 2003; 22 (06) 1007-1018
    CrossrefPubMedGoogle Scholar
  • 6 Yusen RD, Edwards LB, Dipchand AI. , et al; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant 2016; 35 (10) 1170-1184
    CrossrefPubMedGoogle Scholar
  • 7 Finlen Copeland CA, Snyder LD, Zaas DW, Turbyfill WJ, Davis WA, Palmer SM. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med 2010; 182 (06) 784-789
    CrossrefPubMedGoogle Scholar
  • 8 Glanville AR, Gencay M, Tamm M. , et al. Chlamydia pneumoniae infection after lung transplantation. J Heart Lung Transplant 2005; 24 (02) 131-136
    CrossrefPubMedGoogle Scholar
  • 9 Gottlieb J, Zamora MR, Hodges T. , et al. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transplant 2016; 35 (02) 213-221
    CrossrefPubMedGoogle Scholar
  • 10 Allyn PR, Duffy EL, Humphries RM. , et al. Graft loss and CLAD-onset is hastened by viral pneumonia after lung transplantation. Transplantation 2016; 100 (11) 2424-2431
    CrossrefPubMedGoogle Scholar
  • 11 Kaiser L, Aubert JD, Pache JC. , et al. Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med 2006; 174 (12) 1392-1399
    CrossrefPubMedGoogle Scholar
  • 12 Bridevaux PO, Aubert JD, Soccal PM. , et al. Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax 2014; 69 (01) 32-38
    CrossrefPubMedGoogle Scholar
  • 13 Soccal PM, Aubert JD, Bridevaux PO. , et al. Upper and lower respiratory tract viral infections and acute graft rejection in lung transplant recipients. Clin Infect Dis 2010; 51 (02) 163-170
    CrossrefPubMedGoogle Scholar
  • 14 Gerna G, Vitulo P, Rovida F. , et al. Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J Med Virol 2006; 78 (03) 408-416
    CrossrefPubMedGoogle Scholar
  • 15 Khalifah AP, Hachem RR, Chakinala MM. , et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004; 170 (02) 181-187
    CrossrefPubMedGoogle Scholar
  • 16 Kumar D, Erdman D, Keshavjee S. , et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005; 5 (08) 2031-2036
    CrossrefPubMedGoogle Scholar
  • 17 Palmer Jr SM, Henshaw NG, Howell DN, Miller SE, Davis RD, Tapson VF. Community respiratory viral infection in adult lung transplant recipients. Chest 1998; 113 (04) 944-950
    CrossrefPubMedGoogle Scholar
  • 18 Kumar D, Husain S, Chen MH. , et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010; 89 (08) 1028-1033
    CrossrefPubMedGoogle Scholar
  • 19 Milstone AP, Brumble LM, Barnes J. , et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J 2006; 28 (01) 131-137
    CrossrefPubMedGoogle Scholar
  • 20 Weinberg A, Zamora MR, Li S, Torres F, Hodges TN. The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections in lung transplant recipients. J Clin Virol 2002; 25 (02) 171-175
    CrossrefPubMedGoogle Scholar
  • 21 Gottlieb J, Schulz TF, Welte T. , et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation 2009; 87 (10) 1530-1537
    CrossrefPubMedGoogle Scholar
  • 22 Garbino J, Gerbase MW, Wunderli W. , et al. Respiratory viruses and severe lower respiratory tract complications in hospitalized patients. Chest 2004; 125 (03) 1033-1039
    CrossrefPubMedGoogle Scholar
  • 23 Weinberg A, Lyu DM, Li S, Marquesen J, Zamora MR. Incidence and morbidity of human metapneumovirus and other community-acquired respiratory viruses in lung transplant recipients. Transpl Infect Dis 2010; 12 (04) 330-335
    CrossrefPubMedGoogle Scholar
  • 24 Hopkins P, McNeil K, Kermeen F. , et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med 2008; 178 (08) 876-881
    CrossrefPubMedGoogle Scholar
  • 25 Glanville AR, Scott AI, Morton JM. , et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2005; 24 (12) 2114-2119
    CrossrefPubMedGoogle Scholar
  • 26 Gross AE, Bryson ML. Oral ribavirin for the treatment of noninfluenza respiratory viral infections: a systematic review. Ann Pharmacother 2015; 49 (10) 1125-1135
    CrossrefPubMedGoogle Scholar
  • 27 Li L, Avery R, Budev M, Mossad S, Danziger-Isakov L. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2012; 31 (08) 839-844
    CrossrefPubMedGoogle Scholar
  • 28 Fuehner T, Dierich M, Duesberg C. , et al. Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections. Antivir Ther 2011; 16 (05) 733-740
    CrossrefPubMedGoogle Scholar
  • 29 Zamora MR, Budev M, Rolfe M. , et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011; 183 (04) 531-538
    CrossrefPubMedGoogle Scholar
  • 30 DeVincenzo JP, Whitley RJ, Mackman RL. , et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 2014; 371 (08) 711-722
    CrossrefPubMedGoogle Scholar
  • 31 Garbino J, Gerbase MW, Wunderli W. , et al. Lower respiratory viral illnesses: improved diagnosis by molecular methods and clinical impact. Am J Respir Crit Care Med 2004; 170 (11) 1197-1203
    CrossrefPubMedGoogle Scholar
  • 32 Magnusson J, Westin J, Andersson LM, Brittain-Long R, Riise GC. The impact of viral respiratory tract infections on long-term morbidity and mortality following lung transplantation: a retrospective cohort study using a multiplex PCR panel. Transplantation 2013; 95 (02) 383-388
    CrossrefPubMedGoogle Scholar